Unlearn.AI vs OpenAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Unlearn.AI raised $50M+ for its digital twin technology that creates AI-generated control arms for clinical trials, reducing placebo group size and accelerating drug development timelines.
About
Unlearn.AI generates digital twins of clinical trial patients — AI models trained on historical trial data that predict how a specific patient would have responded as a placebo control. By supplementing small placebo control groups with these digital controls, pharmaceutical companies can run trials with fewer placebo patients (or none at all), reducing participant burden, trial costs, and development timelines without sacrificing statistical validity.
GPT-5 and o3 model family at $25B+ ARR; $840B post-money valuation (Feb 2026 round); ChatGPT 1B+ users; largest private fundraise in history ($110B). Competing with Anthropic Claude 4, Google Gemini 3, Meta Llama 4.
About
OpenAI is a San Francisco-based artificial intelligence company developing and deploying large-scale AI systems — including GPT-4o, o1 reasoning models, DALL-E 3 image generation, Sora video generation, and the Whisper speech recognition model — through the ChatGPT consumer product and OpenAI API for developers and enterprise customers. Founded in 2015 as a nonprofit by Sam Altman, Elon Musk, Greg Brockman, and others and restructured into a capped-profit company, OpenAI raised $157 billion in total funding including a $6.6 billion round in October 2024 at a $157 billion valuation and a $40 billion round from SoftBank in 2025, generating $3.7 billion in annualized revenue in 2024 with 400 million weekly ChatGPT users.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.